Penumbra, Inc.

Penumbra, Inc. is an American medical device company headquartered in Alameda, California, focused on developing and marketing innovative therapies for challenging medical conditions, particularly vascular diseases. The company's core business revolves around thrombectomy, utilizing catheters, aspiration systems, and related tools to remove blood clots. Its mission is to improve patient outcomes by providing cutting-edge technology and minimally invasive procedures for serious vascular conditions such as stroke, pulmonary embolism, venous thrombosis, and peripheral arterial disease.

Penumbra's product portfolio includes a range of interventional devices for neurovascular and peripheral vascular applications. Key offerings include aspiration thrombectomy systems like the Indigo platform and Lightning family, used for acute ischemic stroke, pulmonary embolism, and deep vein thrombosis. The company also provides embolization coils, neurosurgical tools such as the Artemis Neuro Evacuation Device, and various access systems. Penumbra serves hospitals and healthcare providers globally, with its products available in over 100 countries.

In a significant development, Boston Scientific announced its intent to acquire Penumbra in a $15 billion cash and stock deal in January 2026, with the transaction anticipated to close by year-end 2026. Recent product innovations include the FDA clearance of THUNDERBOLT, a computer-assisted vacuum thrombectomy (CAVT) system for acute ischemic stroke, in June 2026. Adam Elsesser serves as the Chairman and Chief Executive Officer, while Shruthi Narayan was promoted to President in August 2025. The company continues to expand its thrombectomy platforms and increase international penetration, positioning itself as a leader in mechanical blood clot removal.